|
1
|
Liu J, Ren ZH, Qiang H, Wu J, Shen M,
Zhang L and Lyu J: Trends in the incidence of diabetes mellitus:
Results from the global burden of disease study 2017 and
implications for diabetes mellitus prevention. BMC Public Health.
20(1415)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Arokiasamy P, Salvi S and Selvamani Y:
Global burden of diabetes mellitus. In: Handbook of global health.
Springer, pp1-44, 2021.
|
|
3
|
Kumar R, Saha P, Kumar Y, Sahana S, Dubey
A and Prakash O: A review on diabetes mellitus: Type1 & Type2.
World J Pharm Pharm Sci. 9:838–850. 2020.
|
|
4
|
Ahmad E, Lim S, Lamptey R, Webb DR and
Davies MJ: Type 2 diabetes. Lancet. 400:1803–1820. 2022.
|
|
5
|
Awad SF, Huangfu P, Dargham SR, Ajlouni K,
Batieha A, Khader YS, Critchley JA and Abu-Raddad LJ:
Characterizing the type 2 diabetes mellitus epidemic in Jordan up
to 2050. Sci Rep. 10(21001)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Calle MC and Fernandez ML: Inflammation
and type 2 diabetes. Diabetes Metab. 38:183–191. 2012.
|
|
7
|
Helmersson J, Vessby B, Larsson A and Basu
S: Association of type 2 diabetes with cyclooxygenase-mediated
inflammation and oxidative stress in an elderly population.
Circulation. 109:1729–1734. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Morita I: Distinct functions of COX-1 and
COX-2. Prostaglandins Other Lipid Mediat. 68-69:165–175.
2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Simmons DL, Botting RM and Hla T:
Cyclooxygenase isozymes: The biology of prostaglandin synthesis and
inhibition. Pharmacol Rev. 56:387–437. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Crofford LJ: COX-1 and COX-2 tissue
expression: Implications and predictions. J Rheumatol Suppl.
49:15–19. 1997.PubMed/NCBI
|
|
11
|
Alfadul H, Sabico S and Al-Daghri NM: The
role of interleukin-1β in type 2 diabetes mellitus: A systematic
review and meta-analysis. Front Endocrinol (Lausanne).
13(901616)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tran POT, Gleason CE and Robertson RP:
Inhibition of interleukin-1beta-induced COX-2 and EP3 gene
expression by sodium salicylate enhances pancreatic islet beta-cell
function. Diabetes. 51:1772–1778. 2002.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang G, Liang R, Liu T, Wang L, Zou J, Liu
N, Liu Y, Cai X, Liu Y, Ding X, et al: Opposing effects of
IL-1β/COX-2/PGE2 pathway loop on islets in type 2 diabetes
mellitus. Endocr J. 66:691–699. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fletcher B, Gulanick M and Lamendola C:
Risk factors for type 2 diabetes mellitus. J Cardiovasc Nurs.
16:17–23. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ayelign B, Negash M, Andualem H,
Wondemagegn T, Kassa E, Shibabaw T, Akalu Y and Molla MD:
Association of IL-10 (- 1082 A/G) and IL-6 (- 174 G/C) gene
polymorphism with type 2 diabetes mellitus in Ethiopia population.
BMC Endocr Disord. 21(70)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Momeni-Moghaddam MA, Chahkandi H, Amini
Beidokhti N, Rahmani M, Salarbashi D and Khorasani M:
Angiotensin-converting enzyme I/D gene polymorphism and risk of
type 2 diabetes mellitus in Iranian individuals. Nucleosides
Nucleotides Nucleic Acids. 44:327–336. 2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Alharbi KK, Abudawood M and Khan IA:
Amino-acid amendment of arginine-325-tryptophan in rs13266634
genetic polymorphism studies of the SLC30A8 gene with type 2
diabetes-mellitus patients featuring a positive family history in
the Saudi population. J King Saud Univ Sci. 33(101258)2021.
|
|
18
|
Ozbayer C, Kebapci MN, Degirmenci I, Yagci
E, Gunes HV and Kurt H: Genetic variant in the 3'-untranslated
region of the COX2 gene is associated with type 2 diabetes: A
hospital-based case-control study. Prostaglandins Leukot Essent
Fatty Acids. 137:39–42. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Konheim YL and Wolford JK: Association of
a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2)
with type 2 diabetes mellitus in Pima Indians. Hum Genet.
113:377–381. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Appleby SB, Ristimäki A, Neilson K, Narko
K and Hla T: Structure of the human cyclo-oxygenase-2 gene. Biochem
J. 302:723–727. 1994.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fritsche E, Baek SJ, King LM, Zeldin DC,
Eling TE and Bell DA: Functional characterization of
cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther. 299:468–476.
2001.PubMed/NCBI
|
|
22
|
Perneger TV: What's wrong with Bonferroni
adjustments. BMJ. 316:1236–1238. 1998.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Churm R, Oliver T, Hurel S, Humphries S,
Stephens J and Prior S and Prior S: The-765G> C cyclooxygenase-2
promoter polymorphism is associated with type 2 diabetes mellitus,
low high-density lipoprotein and manifest angina. J Diabetes Metab.
7(2)2016.
|
|
24
|
Martín-Vázquez E, Cobo-Vuilleumier N,
López-Noriega L, Lorenzo PI and Gauthier BR: The
PTGS2/COX2-PGE2 signaling cascade in inflammation: Pro
or anti? A case study with type 1 diabetes mellitus. Int J Biol
Sci. 19:4157–4165. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Oshima H, Taketo MM and Oshima M:
Destruction of pancreatic beta-cells by transgenic induction of
prostaglandin E2 in the islets. J Biol Chem. 281:29330–29336.
2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Rudock ME, Liu Y, Ziegler JT, Allen SG,
Lehtinen AB, Freedman BI, Carr JJ, Langefeld CD and Bowden DW:
Association of polymorphisms in cyclooxygenase (COX)-2 with
coronary and carotid calcium in the diabetes heart study.
Atherosclerosis. 203:459–465. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen W, Ding H, Cheng Y, Li Q, Dai R, Yang
X and Zhang C: Genetic polymorphisms analysis of pharmacogenomic
VIP variants in Bai ethnic group from China. Mol Genet Genomic Med.
7(e884)2019.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Ross S, Eikelboom J, Anand SS, Eriksson N,
Gerstein HC, Mehta S, Connolly SJ, Rose L, Ridker PM, Wallentin L,
et al: Association of cyclooxygenase-2 genetic variant with
cardiovascular disease. Eur Heart J. 35:2242–2248a. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Papafili A, Hill MR, Brull DJ, McAnulty
RJ, Marshall RP, Humphries SE and Laurent GJ: Common promoter
variant in cyclooxygenase-2 represses gene expression: Evidence of
role in acute-phase inflammatory response. Arterioscler Thromb Vasc
Biol. 22:1631–1636. 2002.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wren JD and Garner HR: Data-mining
analysis suggests an epigenetic pathogenesis for type 2 diabetes. J
Biomed Biotechnol. 2005:104–112. 2005.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yang X, Hou F, Taylor L and Polgar P:
Characterization of human cyclooxygenase 2 gene promoter
localization of a TGF-beta response element. Biochim Biophys Acta.
1350:287–292. 1997.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Robertson RP: Dominance of
cyclooxygenase-2 in the regulation of pancreatic islet
prostaglandin synthesis. Diabetes. 47:1379–1383. 1998.PubMed/NCBI View Article : Google Scholar
|
